MiNK Therapeutics Announces First Patient Dosed In Randomized Phase 2 Clinical Trial Evaluating Agent-797 With SOC Vs Placebo With SOC In Patients With Severe Acute Lung Injury And Critical Illness

• First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteria
• Landmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing therapies
• Preliminary data expected in the second half of 2026

NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 with standard of care (SOC) vs placebo with SOC in patients with severe acute lung injury and critical illness.

The first patient was dosed at First Lviv Territorial Medical Union in Lviv, Ukraine, in collaboration with UNBROKEN Ukraine just days after approval from Ministry of health of Ukraine marking the rapid transition from trial activation to treatment administration in a real-world, high-acuity intensive care environment.

The randomized trial, designated C-1300-02, is evaluating agenT-797 plus standard of care compared with placebo plus standard of care in patients with acute lung injury meeting Global Acute Respiratory Distress Syndrome, or ARDS, criteria. The study is designed to evaluate clinically meaningful ICU outcomes, including survival, ventilator-free days, ICU recovery, and biologic measures associated with treatment activity and immune function.